Ascendis Pharma reports Q2 EPS (EUR 0.82) vs. (EUR 2.21) last year

Reports Q2 revenue EUR 158.05M vs. EUR 36M last year. “With the robust global uptake of YORVIPATH and with TransCon CNP under U.S. FDA priority review, Ascendis is on the verge of bringing our third high-value medicine to patients and substantially transforming our financial profile,” said Jan Mikkelsen, Ascendis Pharma’s (ASND) President and Chief Executive Officer. “We expect our engine for future innovation to drive continued momentum as we aim to address unmet medical need in endocrine rare diseases and other large indications for years to come on our path to fulfilling Vision 2030.”